

Country Oncology Report

May 2016

## nutritionDay November 2015 in SPAIN

Dear participant,

thank you for your participation in nutritionDay worldwide in November 2015 and for your effort. We are now able to present you your oncology country report of the following sample size.

Number of units on nutritionDay: 15 Number of units on nutritionDay completing Sheet 1\_onco: 4 Number of patients on nutritionDay: 400 Number of cancer patients on nutritionDay: 53 (referring to sheet 2 regular "affected organs") Number of patients completing Sheet 2\_onco: 30 Number of patients completing Sheet 3 onco: 30

Your oncology report reference results are based on data of cancer patients of all specialties of nutritionDay 2015.

The nutritionDay oncology report provides most important results of your oncology patients as well as nutritional care structures and care routines for cancer patients in your country.

You will find some explanations how to read and interpret the data on the next page.

Next year's nutritionDay will take place on November 10<sup>th</sup> 2016. Again, we would very much appreciate your participation. You will be provided with further information on a regular basis.

Best regards from the nutritionDay-Team!

Prof. Dr. Michael Hiesmayr

Clarak

Sigrid Kosak, MA



UNITS REPORT ("Sheet 1"):	YOUR RESULTS	REFERENCE RESULTS
Number of units with cancer patients:	4	275
Computerized system in hospital:	4 units (100%) YES	262 units (95%) YES
Nutritional treatment of cancer patients is part of overall care plan	4 units (100%) YES	245 units (89%) YES
Nutritional treatment is considered Routinely When patient asks When body weight loss > 10% During palliative phase Other Missing	2 (50.0%) 1 (25.0%) 1 (25.0%) 1 (25.0%) - -	
Nutritional treatment is not part of the comprehensive approach due to Lack of evidence No knowledge of the field No reimbursement It feeds the tumour Other	- - - -	6 (2.18%) 11 (4.00%) 8 (2.91%) - 16 (5.82%)
Nutritional therapy used for cancer patients Nutrition according to nutrition plan Calculation of energy needs Monitoring patients intake and use of oral supplements None Other Missing	3 (75.0%) - 2 (50.0%) - - -	195 (70.9%) 164 (59.6%) 242 (88.0%) - 26 (9.45%) 6 (2.18%)
Nutritional therapy is not used due to Lack of evidence Lack of experience No reimbursement Lack of dietitians Lack of other experts Other Missing	- - 1 (25.0%) - -	2 (0.73%) 5 (1.82%) 6 (2.18%) 8 (2.91%) 1 (0.36%) 7 (2.55%)
Assessment of parameters in cancer patients & methods used:		
Anthropometry/Body composition: Body weight Regularly At chemotherapy When necessary Never Unknown Missing	2 (50.0%) 2 (50.0%) - - - -	



Anthropometrics (circumference	20)		
Regularly			25 (9.09%)
At chemotherapy		_	9 (3.27%)
When necessary		_	89 (32.4%)
Never		4 (100%)	122 (44.4%)
Unknown		4 (10070)	8 (2.91%)
		-	· · /
Missing		-	22 (8.00%)
BIA			
Regularly		_	3 (1.09%)
At chemotherapy		_	3 (1.0770)
When necessary		_	68 (24.7%)
Never		4 (100%)	162 (58.9%)
Unknown		4 (10070)	18 (6.55%)
Missing		-	24 (8.73%)
IVIISSII IG		-	24 (0.7370)
CT SCAN			
Regularly		-	10 (3.64%)
At chemotherapy		-	
When necessary		_	84 (30.5%)
Never		4 (100%)	139 (50.5%)
Unknown		- (10070)	14 (5.09%)
Missing		-	28 (10.2%)
IVIISSII IG		-	20 (10.270)
DEXA			
Regularly		-	3 (1.09%)
At chemotherapy		-	2 (0.73%)
When necessary		-	60 (21.8%)
Never		4 (100%)	159 (57.8%)
Unknown		- (10070)	20 (7.27%)
Missing		_	31 (11.3%)
1VIISSI 19			51 (11.570)
Other (body composition)			
Regularly		1 (25.0%)	6 (2.18%)
At chemotherapy		-	-
When necessary		-	24 (8.73%)
Never		3 (75.0%)	85 (30.9%)
Unknown		-	34 (12.4%)
Missing		-	126 (45.8%)
i i i i i i i i i i i i i i i i i i i			
Body function:			
Handgrip			
Regularly		-	15 (5.45%)
At chemotherapy		-	1 (0.36%)
When necessary		-	62 (22.5%)
Never		4 (100%)	167 (60.7%)
Unknown		-	8 (2.91%)
Missing		-	22 (8.00%)
5			. ,
6-minutes walking test			
Regularly		-	4 (1.45%)
At chemotherapy		1 (25.0%)	2 (0.73%)
When necessary		-	53 (19.3%)
Never		3 (75.0%)	182 (66.2%)
Unknown		-	7 (2.55%)
putritionDay Nay 2015	10/05/2016 12:14		
nutritionDay Nov. 2015	10/05/2016 12:14 - Page 3 of 11		

nutritionDay

Missing		-	27 (9.82%)
Other (body function)			
Regularly		-	2 (0.73%)
At chemotherapy		-	1 (0.36%)
When necessary		1 (25.0%)	28 (10.2%)
Never		3 (75.0%)	109 (39.6%)
Unknown		-	32 (11.6%)
Missing		-	103 (37.5%)
Nutritional requirements, calc	culated		
Regularly		-	71 (25.8%)
At chemotherapy		-	4 (1.45%)
When necessary		1 (25.0%)	113 (41.1%)
Never		3 (75.0%)	29 (10.5%)
Unknown		-	5 (1.82%)
Missing		-	53 (19.3%)
Nutritional intake:			
Every meal			
Regularly		1 (25.0%)	66 (24.0%)
At chemotherapy		-	2 (0.73%)
When necessary		1 (25.0%)	117 (42.5%)
Never		2 (50.0%)	40 (14.5%)
Unknown		_ (000000)	8 (2.91%)
Missing		-	42 (15.3%)
			12 (10.070)
1 meal per day Regularly		_	20 (7.27%)
At chemotherapy		-	1 (0.36%)
When necessary		1 (25.0%)	66 (24.0%)
Never		3 (75.0%)	65 (23.6%)
Unknown		3 (73.070)	18 (6.55%)
Missing		-	105 (38.2%)
IVIISSII IG		-	105 (38.276)
2 meals per day Regularly			17 (6.18%)
At chemotherapy		-	2 (0.73%)
			• •
When necessary		1 (25.0%)	66 (24.0%)
Never		3 (75.0%)	69 (25.1%) 19 (6 55%)
Unknown		-	18 (6.55%)
Missing		-	103 (37.5%)
24h recall			10 /17 50/1
Regularly		1 (25.0%)	48 (17.5%)
At chemotherapy			2 (0.73%)
When necessary		1 (25.0%)	85 (30.9%)
Never		2 (50.0%)	50 (18.2%)
Unknown Missing		-	14 (5.09%) 76 (27.6%)
_			
Other (nutritional intake) Regularly		_	12 (4.36%)
At chemotherapy		-	1 (0.36%)
		-	36 (13.1%)
When necessary		-	30 (13.1%)
nutritionDay Nov. 2015	10/05/2016 12:14 - Page 4 of 11		

Never	4 (100%)	58 (21.1%)
Unknown	-	26 (9.45%)
Missing	-	142 (51.6%)
Questionnaire completed by		
Dietitian	1 (25.0%)	100 (36.4%)
Nurse	3 (75.0%)	105 (38.2%)
Physician	-	43 (15.6%)
Nutritional scientist	-	19 (6.91%)
Other	-	4 (1.45%)
Missing	-	4 (1.45%)



PATIENTS REPORT ("Sheet 2")	):	YOUR RESULTS	REFERENCE RESULTS
Number of patients completin		30	2607
Demographic data:			
Age (years)		72 [16-89]	65 [3-105]
Female gender		8 (26.7%)	1167 (44.8%)
Weight (kg)		70.7 ± 20.7	68.0 ± 17.1
Height (cm) BMI (kg/m2)		163.8 ± 7.0 26.4 ± 7.2	166.2 ± 10.3 24.4 ± 5.2
		20.4 ± 7.2	24.4 ± 5.2
Outpatient (o)/Ward (w)			
Outpatient(o)		3 (10.0%)	22 (0.84%)
Ward (w) Missing		27 (90.0%)	2580 (99.0%) 5 (0.19%)
IVIISSII IG		-	5 (0.19%)
Goal of Therapy			
		15 (50.0%)	1402 (53.8%)
Palliative Terminal		6 (20.0%)	1006 (38.6%) 113 (4.33%)
Missing		- 9 (30.0%)	86 (3.30%)
Reason for admission			
Clinical diagnostics Therapy		6 (20.0%) 6 (20.0%)	355 (13.6%) 1228 (47.1%)
Surgery related		4 (13.3%)	423 (16.2%)
Treatment complications		2 (6.67%)	365 (14.0%)
Poor health status		15 (50.0%)	418 (16.0%)
Independent care difficult		-	38 (1.46%)
Missing		-	-
Present cancer diagnosis			
Breast		1 (3.33%)	180 (6.90%)
Colon, rectum Prostate		4 (13.3%) 2 (6.67%)	427 (16.4%) 98 (3.76%)
Lung		3 (10.0%)	312 (12.0%)
Skin		-	35 (1.34%)
Kidney/bladder		9 (30.0%)	126 (4.83%)
Gastric/oesophageal		1 (3.33%)	274 (10.5%)
Pancreas Lymphoma		1 (3.33%) 6 (20.0%)	126 (4.83%) 165 (6.33%)
Ears nose throat (ENT)		4 (13.3%)	171 (6.56%)
Leukaemia		1 (3.33%)	163 (6.25%)
Genital tract		2 (6.67%)	121 (4.64%)
Liver		-	123 (4.72%)
Sarcoma Brain		-	41 (1.57%) 54 (2.07%)
Testicular		-	54 (2.07%) 17 (0.65%)
Other		-	257 (9.86%)
Missing		-	108 (4.14%)
Time since diagnosis			
0-2 months		6 (20.0%)	777 (29.8%)
3-5 months		5 (16.7%)	412 (15.8%)
6-12 months		5 (16.7%)	388 (14.9%)
nutritionDay Nov. 2015	10/05/2016 12:14 - Page 6 of 11		

nutritionDay

14 years       5 (16,7%)       223 (8,909         4 years       264 (10,33         16sing       1 (3,33%)       172 (6,609         2-Carcinoma in situ       1 (3,33%)       90 (3,459         1-Carcinoma in situ       5 (16,7%)       345 (13,29         1-Late locally advanced       5 (16,7%)       325 (15,09         V-Metastasted       6 (20,0%)       955 (36,66)         Motherapy statt       0 (33,3%)       450 (17,39         umour staging/diagnosis       3 (10,0%)       200 (7,679         12 months       1 (3,33%)       345 (13,29         12 wars       2 (6,67%)       236 (90,09         14 years       2 (6,67%)       176 (6,7%)         12 wars       1 (3,33%)       163 (6,259         herapy situation       -       227 (10,49         12 adotherapy       -       212 (10,49     <			
4 years       266 (0.39         Aissing       1 (3.33%)       172 (6.60)         Cancer staging       -	1-2 years	• •	314 (12.0%
Alissing       1 (3.33%)       172 (6.609         Cancer slaging       1       1 (3.33%)       90 (3.459         Localized       3 (10.0%)       375 (14.4%)         =Early locally advanced       5 (16.7%)       334 (13.29)         =Late localized       6 (20.0%)       955 (36.6%)         Alissing       10 (33.3%)       450 (17.3%)         ime since first therapy start       6 (20.0%)       226 (28.29)         >Lo months       7 (23.3%)       736 (28.29)         >Lo months       1 (3.33%)       345 (13.29)         >La months       2 (6.67%)       176 (6.75)         >La years       2 (6.67%)       176 (6.75)         >La years       2 (6.67%)       163 (6.059)         herapy situation       -       -       27 (10.49)         arget therapy > 1st line       3 (10.0%)       367 (14.19)	2-4 years	5 (16.7%)	232 (8.90%
Cancer staging         Image: Staging stage           I=Carcinoma in situ         1 (3.33%)         90 (3.459           I=Carcinoma in situ         1 (3.33%)         90 (3.459           I=Carcinoma in situ         1 (3.33%)         90 (3.459           I=Carcinoma in situ         5 (16.7%)         332 (15.09           I=Late locally advanced         5 (16.7%)         332 (15.09           V=Metastasised         6 (20.0%)         955 (36.69           Jissing         10 (33.3%)         187 (7.179           Immour staging/diagnosis         3 (10.0%)         200 (76.779           P months         1 (3.33%)         187 (7.179           Immour staging/diagnosis         3 (10.0%)         200 (76.779           P months         1 (3.33%)         187 (1.719           P amonths         1 (3.33%)         187 (1.329           -12 months         6 (20.0%)         238 (13.00           -2 years         6 (20.0%)         238 (13.00           -2 years         2 (6.67%)         176 (6.759           -2 years         2 (6.67%)         16.078           -2 gats         5 (16.7%)         236 (9.059           Chemotherapy 1st line         4 (13.3%)         488 (18.79           Chemotherapy 1st line	> 4 years	-	268 (10.3%
I⊢Carcinoma în situ 1 (3.33%) 90 (3.45) ⊢Localized 3 (10.0%) 375 (14.49 ⊢Eatry localiy advanced 5 (16.7%) 335 (13.29 I⊨Late locally advanced 5 (16.7%) 335 (13.29 I⊨Late locally advanced 6 (20.0%) 955 (36.69 Alissing 10 (33.3%) 450 (17.39 Ime since first therapy start io therapy 4 (13.3%) 187 (7.179 umour staging/diagnosis 3 (10.0%) 200 (7.679 ⊥2 months 7 (23.3%) 736 (28.29 -5 months 1 (3.33%) 345 (13.29 -2 years 6 (20.0%) 233 (13.09 -2 years 6 (20.0%) 233 (13.09 -2 years 6 (20.0%) 233 (13.09 -2 years 1 (3.33%) 163 (62.59 herapy situation herapy situation herapy situation herapy 1st line 4 (13.3%) 163 (62.59 herapy situation Aligenosis 5 (16.7%) 236 (9.059 Alissing 1 (3.33%) 163 (62.59 herapy situation herapy 1st line 4 (13.3%) 163 (62.59 herapy situation herapy 1st line 3 (10.0%) 367 (14.19 arget therapy - 84 (3.229 tormone therapy 1st line 3 (10.0%) 367 (14.19 arget therapy - 84 (3.229 tormone therapy 1st line 3 (10.0%) 367 (14.19 arget therapy - 84 (3.229 tormone therapy 1st line 3 (10.0%) 367 (14.19 arget related complications 5 (16.7%) 504 (19.39 ancer related complications 5 (16.7%) 504 (19.39 ancer related complications 5 (16.7%) 504 (19.39 ancer related complications 5 (16.7%) 381 (14.66 Seneral 4 (13.3%) 179 (68.79 Missing 6 (20.0%) 153 (5.879 microtions	Missing	1 (3.33%)	172 (6.60%
I⊢Carcinoma în situ 1 (3.33%) 90 (3.45) ⊢Localized 3 (10.0%) 375 (14.49 ⊢Eatry localiy advanced 5 (16.7%) 335 (13.29 I⊨Late locally advanced 5 (16.7%) 335 (13.29 I⊨Late locally advanced 6 (20.0%) 955 (36.69 Alissing 10 (33.3%) 450 (17.39 Ime since first therapy start io therapy 4 (13.3%) 187 (7.179 umour staging/diagnosis 3 (10.0%) 200 (7.679 ⊥2 months 7 (23.3%) 736 (28.29 -5 months 1 (3.33%) 345 (13.29 -2 years 6 (20.0%) 233 (13.09 -2 years 6 (20.0%) 233 (13.09 -2 years 6 (20.0%) 233 (13.09 -2 years 1 (3.33%) 163 (62.59 herapy situation herapy situation herapy situation herapy 1st line 4 (13.3%) 163 (62.59 herapy situation Aligenosis 5 (16.7%) 236 (9.059 Alissing 1 (3.33%) 163 (62.59 herapy situation herapy 1st line 4 (13.3%) 163 (62.59 herapy situation herapy 1st line 3 (10.0%) 367 (14.19 arget therapy - 84 (3.229 tormone therapy 1st line 3 (10.0%) 367 (14.19 arget therapy - 84 (3.229 tormone therapy 1st line 3 (10.0%) 367 (14.19 arget therapy - 84 (3.229 tormone therapy 1st line 3 (10.0%) 367 (14.19 arget related complications 5 (16.7%) 504 (19.39 ancer related complications 5 (16.7%) 504 (19.39 ancer related complications 5 (16.7%) 504 (19.39 ancer related complications 5 (16.7%) 381 (14.66 Seneral 4 (13.3%) 179 (68.79 Missing 6 (20.0%) 153 (5.879 microtions	Cancer staging		
Localized 3 (10.0%) 375 (14.49 =Early locally advanced 5 (16.7%) 332 (15.0% V-Metastasised 6 (20.0%) 955 (36.6% dissing 10 (33.3%) 450 (17.39 ime since first therapy start io therapy 4 (13.3%) 187 (7.179 umour staging/diagnosis 3 (10.0%) 200 (7.67) -2 months 7 (23.3%) 736 (28.29 -5 months 1 (3.33%) 345 (13.29 -12 months 6 (20.0%) 328 (13.00%) -2 years 7 (23.3%) 256 (9.5%) -4 years 1 (3.33%) 250 (9.5%) -4 years 1 (3.33%) 250 (9.5%) -4 years 1 (3.33%) 250 (9.5%) -2 montherapy 1st line 4 (13.3%) 163 (6.25) herapy situation 2 ingerty - 2 (16.4%) 236 (9.05%) -2 montherapy 1st line 4 (13.3%) 163 (6.25%) -2 comone therapy - 1st line 3 (10.0%) 367 (14.19 2 adjotherapy - 2 (6.67%) 359 (13.88) -2 (10.0%) 26 (10.0%) 26 (10.29) -2 (10.0%) 26 (10.29) -2 (10.0%) 26 (10.29) -2 (10.0%) 26 (10.09) 26 (10.29) -2 (10.0%) 27 (13.1%) 27 (14.19) -2 (10.0%) 26 (10.29) -2 (10.0%) 26 (10.09) 26 (10.09) -2 (10.0%) 27 (14.19) -2 (10.0%) 27 (14.19) -2 (10.0%) 27 (14.19) -2 (10.0%) 37 (10.0%) 37 (10.0%) -2		1 (3 33%)	90 (3 15%
=Early locally advanced         5 (16.7%)         345 (13.29           I=Late locally advanced         5 (16.7%)         392 (15.0%)           V=Metastssed         6 (20.0%)         955 (36.69           dissing         10 (33.3%)         450 (17.39           ime since first therapy start         unour staging/diagnosis         3 (10.0%)         200 (7.67)           >2 months         7 (23.3%)         736 (28.29         -5           >-12 months         1 (3.33%)         453 (13.09)           -2 wears         6 (20.0%)         338 (13.09)           -2 years         6 (20.0%)         338 (13.09)           -2 years         6 (20.0%)         238 (13.09)           -4 years         1 (3.33%)         250 (9.59)           dissing         1 (3.33%)         260 (9.59)           herapy situation         -         272 (10.4%)           arget therapy         -         246 (9.05)           Chemotherapy 1st line         3 (10.0%)         367 (14.19)           addotherapy         -         226 (9.059)           deatotherapy         -         272 (10.4%)           arget therapy         -         272 (10.4%)           arget therapy         -         272 (10.4%) <t< td=""><td></td><td>• •</td><td>•</td></t<>		• •	•
II-LaTe locally advanced       5 (16.7%)       392 (15.0%)         V-Metastasised       6 (20.0%)       955 (36.6%)         Vising       10 (33.3%)       450 (17.3%)         ime since first therapy stat		• • •	•
V-Metastassed       6 (20.0%)       955 (36.69)         Missing       10 (33.3%)       450 (17.39)         ime since first therapy start       3 (10.0%)       200 (7.67)         uonus tagging/diagnosis       3 (10.0%)       200 (7.67)         12 months       7 (23.3%)       376 (28.27)         12 months       7 (23.3%)       376 (28.27)         12 months       6 (20.0%)       338 (13.09)         -2 years       6 (20.0%)       338 (13.09)         -2 years       6 (20.0%)       328 (13.09)         -2 years       6 (20.0%)       328 (13.09)         -2 years       6 (20.0%)       328 (13.09)         -2 years       6 (20.0%)       338 (13.09)         -2 years       6 (20.0%)       338 (13.09)         -2 years       6 (20.0%)       136 (6.75)         -2 years       2 (6.67%)       16 (6.75)         -2 gotomotherapy statine       3 (10.0%)       367 (14.19)         -2 gotomotherapy 1st line       4 (13.3%)       488 (18.79)         -2 pears       2 (6.67%)       359 (13.89)         uorgery       -2 (6.67%)       359 (13.89)         uorgery       2 (6.67%)       506 (10.29)         herapy related complications		• • •	•
Alissing       10 (33.3%)       450 (17.39)         ime since first therapy start	5	• •	•
ime since first therapy start       4 (13.3%)       187 (7.179         umour staging/diagnosis       3 (10.0%)       200 (7.67)         2-2 months       7 (23.3%)       736 (28.29)         2-5 months       1 (3.33%)       345 (13.29)         2-12 months       6 (20.0%)       238 (13.09)         2-2 years       6 (20.0%)       232 (8.909)         -4 years       2 (6.67%)       176 (6.75)         4 years       2 (6.67%)       176 (6.75)         -4 years       2 (6.67%)       166 (6.75)         herapy situation       20       272 (10.49)         Diagnosis       5 (16.7%)       236 (9.059)         herenotherapy 1st line       4 (13.3%)       488 (18.79)         Chemotherapy 1st line       3 (10.0%)       367 (14.19)         2 dormone therapy       - 26 (1.009)       272 (10.49)         arget therapy       - 26 (1.009)       26 (10.29)         satising       2 (6.67%)       504 (19.39)         Cancer related complications       5 (16.7%)       266 (10.29)         herapy related complications       5 (16.7%)       311 (14.69)         Sciencral       4 (13.3%)       179 (68.3%)       190 (68.13%)         Jocal       5 (16.7%)       326 (10.9		· · ·	•
lot herapy       4 (13.3%)       187 (7.17)         umour staging/diagnosis       3 (10.0%)       200 (7.67)         2 months       7 (23.3%)       736 (28.2%)         15 months       1 (3.33%)       345 (13.2%)         -12 months       6 (20.0%)       238 (13.0%)         -2 years       6 (20.0%)       228 (8.0%)         -4 years       2 (6.67%)       176 (6.75)         -4 years       2 (6.67%)       13.33%)       163 (6.259)         herapy situation       1 (3.33%)       236 (9.05)         Diagnosis       5 (16.7%)       236 (9.05)         Chemotherapy 1st line       4 (13.3%)       488 (18.79)         Chemotherapy 1st line       3 (10.0%)       367 (14.19)         addotherapy       -       22 (10.44)         arget therapy       -       84 (3.229)         formone therapy       -       26 (10.09)         alliative       2 (6.67%)       504 (19.39)         carget related complications       5 (16.7%)       266 (10.29)         dising       6 (20.0%)       153 (5.879)         floate       19 (63.3%)       1808 (69.49)         carget related complications       5 (16.7%)       239 (9.179)         Missing		10 (33.370)	450 (17.570
umour staging/diagnosis         3 (10.0%)         200 (7.67)           2 months         7 (23.3%)         736 (28.29)           -12 months         1 (3.33%)         3345 (13.29)           -12 months         6 (20.0%)         232 (8.90)           -2 years         6 (20.0%)         232 (8.90)           -4 years         2 (6.67%)         176 (6.75)           -4 years         1 (3.33%)         163 (6.259)           herapy situation         1         (3.33%)         163 (6.259)           herapy situation         1         23.3(%)         236 (9.05)           chemotherapy 1st line         4 (13.3%)         488 (18.79)           chemotherapy > 1st line         3 (10.0%)         367 (14.19)           adiotherapy         -         272 (10.49)           arget therapy         -         246 (10.0%)           'alliative         2 (6.67%)         359 (13.89)           urgery         2 (6.67%)         504 (19.39)           chace related complications         5 (16.7%)         266 (10.29)           herapy related complications         5 (16.7%)         380 (64.49)           ocal         9 (63.3%)         1808 (69.49)           ocal         9 (16.7%)         381 (14.69) <tr< td=""><td>Time since first therapy start</td><td></td><td></td></tr<>	Time since first therapy start		
1-2 months       7 (23.3%)       736 (28.29         1-5 months       1 (3.33%)       345 (13.29         -12 months       6 (20.0%)       328 (13.09         -2 years       6 (20.0%)       232 (8.909         -4 years       2 (6.67%)       176 (6.759         4 years       1 (3.33%)       163 (6.259         herapy situation       1       1 (3.33%)       163 (6.259         herapy situation       2       -       272 (10.49         Chemotherapy 1st line       4 (13.3%)       488 (18.79         Chemotherapy 1st line       3 (10.0%)       367 (14.19         Caldotherapy       -       272 (10.49         arget therapy       -       84 (3.229         formone therapy       -       84 (3.229         barrey related complications       5 (16.7%)       266 (10.29         herapy related complications       5 (16.7%)       266 (10.29         herapy related complications       3 (10.0%)       127 (4.87         Alsing       6 (20.0%)       153 (5.879         nfections       -       -         lone       19 (63.3%)       1808 (69.49         ocal       5 (16.7%)       239 (9.179         Missing       2 (6.67%)	No therapy	4 (13.3%)	187 (7.17%
15 months       1 (3.33%)       345 (13.29         -12 months       6 (20.0%)       338 (13.09         -2 years       6 (20.0%)       232 (8.90         2-4 years       2 (6.67%)       176 (6.759         4 years       1 (3.33%)       250 (9.599         herapy situation       2       2         bargotis       5 (16.7%)       236 (9.059         chemotherapy situation       3 (10.0%)       367 (14.19         Chemotherapy 1st line       4 (13.3%)       488 (18.79         Chemotherapy 1st line       3 (10.0%)       367 (14.19         Chemotherapy 1st line       4 (3.229       -         formone therapy       -       84 (3.229         formone therapy       -       84 (3.229         formone therapy       -       26 (6.7%)         calcetrelated complications       5 (16.7%)       266 (10.29         herapy related complications       5 (16.7%)       266 (10.29         herapy related complications       3 (10.0%)       127 (4.879         ocal       5 (16.7%)       381 (14.69         General       1 (3.3%)       179 (6.87%)         Jose       1 (5 (50.0%)       1080 (41.49         ocal       5 (50.0%)       1080 (	Tumour staging/diagnosis	3 (10.0%)	200 (7.67%
12 months       6 (20.0%)       338 (13.0%)         -2 years       6 (20.0%)       232 (8.9%)         14 years       2 (6.67%)       176 (6.75%)         4 years       1 (3.33%)       250 (9.59%)         Missing       1 (3.33%)       163 (6.25%)         herapy situation       0       236 (9.05%)         Diagnosis       5 (16.7%)       236 (9.05%)         Chemotherapy 1st line       4 (13.3%)       488 (18.7%)         Chemotherapy > 1st line       3 (10.0%)       367 (14.1%)         Chornot therapy       -       272 (10.4%)         arget therapy       -       24 (3.20%)         formone therapy       -       26 (10.0%)         arget therapy       -       26 (10.9%)         arget therapy       -       26 (10.9%)         arget therapy       -       26 (10.9%)         arget therapy       2 (6.67%)       504 (19.3%)         Cancer related complications       5 (16.7%)       266 (10.2%)         berapy related complications       5 (16.7%)       381 (14.6%)         General       4 (13.3%)       179 (6.87%)         dotal       5 (16.7%)       381 (14.6%)         General       4 (13.3%)       179 (6.87%)	0-2 months	7 (23.3%)	736 (28.2%
-2 years       6 (20.0%)       232 (8.90)         -4 years       2 (6.67%)       176 (6.75)         Alissing       1 (3.33%)       250 (9.59)         herapy situation       1       (3.33%)       163 (6.25)         heraps situation       2       2       (9.05)         Chemotherapy 1st line       4 (13.3%)       488 (18.7)         Chemotherapy 1st line       3 (10.0%)       367 (14.1)         adotherapy       -       272 (10.4)         arget therapy       -       84 (3.22)         formone therapy       -       26 (10.0%)         arget therapy       -       26 (10.0%)         arget therapy       -       26 (10.29)         formone therapy       -       26 (10.29)         arget therapy       -       26 (10.29)         arget therapy       -       26 (10.29)         formone therapy       2 (6.67%)       504 (19.3)         laising       6 (20.0%)       153 (5.87)         formeact related complications       3 (10.0%)       127 (4.87)         herapy related complications       5 (16.7%)       381 (14.6)         General       4 (13.3%)       179 (6.87)         occal       5 (16.7%)       381	3-5 months	1 (3.33%)	345 (13.2%
-2 years       6 (20.0%)       232 (8.90)         -4 years       2 (6.67%)       176 (6.75)         Alissing       1 (3.33%)       250 (9.59)         herapy situation       1       (3.33%)       163 (6.25)         heraps situation       2       2       (9.05)         Chemotherapy 1st line       4 (13.3%)       488 (18.7)         Chemotherapy 1st line       3 (10.0%)       367 (14.1)         adotherapy       -       272 (10.4)         arget therapy       -       84 (3.22)         formone therapy       -       26 (10.0%)         arget therapy       -       26 (10.0%)         arget therapy       -       26 (10.29)         formone therapy       -       26 (10.29)         arget therapy       -       26 (10.29)         arget therapy       -       26 (10.29)         formone therapy       2 (6.67%)       504 (19.3)         laising       6 (20.0%)       153 (5.87)         formeact related complications       3 (10.0%)       127 (4.87)         herapy related complications       5 (16.7%)       381 (14.6)         General       4 (13.3%)       179 (6.87)         occal       5 (16.7%)       381	6-12 months	6 (20.0%)	338 (13.0%
24 years       2 (6.67%)       176 (6.759)         4 years       1 (3.33%)       250 (9.59)         herapy situation       0       13.33%)       163 (6.259)         herapy situation       236 (9.059)       236 (9.059)         Chemotherapy 1st line       4 (13.3%)       488 (18.79)         Chemotherapy > 1st line       3 (10.0%)       367 (14.19)         araget therapy       -       272 (10.44)         araget therapy       -       24 (3.229)         Jornone therapy       -       26 (1.00)         Palliative       2 (6.67%)       359 (13.89)         urgery       2 (6.67%)       504 (19.39)         Cancer related complications       5 (16.7%)       266 (10.29)         herapy related complications       5 (16.7%)       281 (14.69)         Jissing       6 (20.0%)       153 (5.87)         nfections       -       -         Jurition Treatment       -       -         Jos special diet       15 (50.0%)       1080 (41.49)         ndividualized diet plan       7 (23.3%)       572 (21.99)         interal nutrition (via NGT/PEG)       3 (10.0%)       128 (4.91)         ONS enriched with special nutrients       -       88 (3.38)      <	1-2 years	• •	232 (8.90%
4 years       1 (3.33%)       250 (9.599         Missing       1 (3.33%)       163 (6.259         herapy situation       0       236 (9.059         Diagnosis       5 (16.7%)       236 (9.059         Chemotherapy 1st line       4 (13.3%)       488 (18.7%)         Chemotherapy 1st line       3 (10.0%)       367 (14.19         araget therapy       -       272 (10.49         arget therapy       -       26 (10.09         Palliative       2 (6.67%)       359 (13.89         urgery       2 (6.67%)       504 (19.39         Cancer related complications       5 (16.7%)       266 (10.29         herapy related complications       5 (16.7%)       266 (10.29         herapy related complications       5 (16.7%)       288 (69.49         vone       19 (63.3%)       1808 (69.49         vocal       5 (16.7%)       381 (14.69         General       4 (13.3%)       179 (6.87%         Missing       2 (6.67%)       239 (9.179         Mutrition Treatment       2       2 (6.67%)       239 (9.179         Mutrition Via NGT/PEG)       3 (10.0%)       128 (4.919         Variation Treatment       -       2 (6.67%)       226 (16.39	2-4 years	· · ·	176 (6.75%
Missing       1 (3.33%)       163 (6.259         herapy situation       233%)       236 (9.059         Chemotherapy 1st line       4 (13.3%)       488 (18.79         Chemotherapy 1st line       3 (10.0%)       367 (14.19         adiotherapy       -       272 (10.49         arget therapy       -       84 (3229         formone therapy       -       26 (10.0%)         arget therapy       -       84 (3229         formone therapy       -       26 (10.0%)         arget therapy       -       26 (10.29         formone therapy       2 (6.67%)       504 (19.39         Cancer related complications       5 (16.7%)       266 (10.29         herapy related complications       3 (10.0%)       127 (4.879         Alissing       6 (20.0%)       153 (5.879         nfections       -       -         None       19 (63.3%)       1808 (69.49         ocal       5 (16.7%)       381 (14.69         Seneral       4 (13.3%)       179 (6.879         Alissing       2 (6.67%)       239 (9.179         Mutrition Treatment       -       -       239 (9.179         Vatrition Treatment       -       -       - <td></td> <td>· · ·</td> <td>•</td>		· · ·	•
Diagnosis       5 (16.7%)       236 (9.059         Chemotherapy 1st line       4 (13.3%)       488 (18.79         Chemotherapy > 1st line       3 (10.0%)       367 (14.19         adiotherapy       -       212 (10.49         arget therapy       -       84 (3.229         formone therapy       -       26 (1.009         alliative       2 (6.67%)       359 (13.89         burgery       2 (6.67%)       504 (19.39         cancer related complications       5 (16.7%)       266 (10.29         herapy related complications       3 (10.0%)       127 (4.879         Alissing       6 (20.0%)       153 (5.879         nfections       -       2 (6.67%)       381 (14.69         General       4 (13.3%)       179 (6.879         vising       2 (6.67%)       239 (9.179         Autrition Treatment       -       -         vospecial diet       15 (50.0%)       1080 (41.49         nacterial nutrition (via NGT/PEG)       3 (10.0%)       128 (4.919         varenteral nutrition       -       88 (3.38)       240 (9.219         DNS enriched with special nutrients       -       88 (3.389       -         opecial nutrients (EPA, branched chained amino       - </td <td>Missing</td> <td>• •</td> <td>163 (6.25%</td>	Missing	• •	163 (6.25%
Diagnosis       5 (16.7%)       236 (9.059         Chemotherapy 1st line       4 (13.3%)       488 (18.79         Chemotherapy > 1st line       3 (10.0%)       367 (14.19         adiotherapy       -       212 (10.49         arget therapy       -       84 (3.229         formone therapy       -       26 (1.009         alliative       2 (6.67%)       359 (13.89         burgery       2 (6.67%)       504 (19.39         cancer related complications       5 (16.7%)       266 (10.29         herapy related complications       3 (10.0%)       127 (4.879         Alissing       6 (20.0%)       153 (5.879         nfections       -       2 (6.67%)       381 (14.69         General       4 (13.3%)       179 (6.879         vising       2 (6.67%)       239 (9.179         Autrition Treatment       -       -         vospecial diet       15 (50.0%)       1080 (41.49         nacterial nutrition (via NGT/PEG)       3 (10.0%)       128 (4.919         varenteral nutrition       -       88 (3.38)       240 (9.219         DNS enriched with special nutrients       -       88 (3.389       -         opecial nutrients (EPA, branched chained amino       - </td <td></td> <td></td> <td></td>			
Chemotherapy 1st line       4 (13.3%)       488 (18.79         Chemotherapy > 1st line       3 (10.0%)       367 (14.19         Radiotherapy       -       272 (10.49         arget therapy       -       84 (3.229         domone therapy       -       26 (1.009         Palliative       2 (6.67%)       359 (13.89         surgery       2 (6.67%)       504 (19.39         Cancer related complications       5 (16.7%)       266 (10.29         herapy related complications       3 (10.0%)       127 (4.87)         Alissing       6 (20.0%)       153 (5.879         nfections       3 (10.67%)       381 (14.69         vone       19 (63.3%)       1808 (69.49         ocal       5 (16.7%)       381 (14.69         Seneral       4 (13.38)       179 (6.879         Alissing       2 (6.67%)       239 (9.179         Nutrition Treatment       4 (13.3%)       179 (6.879         No special diet       15 (50.0%)       1080 (41.49         ndividualized diet plan       7 (23.3%)       572 (21.99         interal nutrition (via NGT/PEG)       3 (10.0%)       128 (4.919         Parenteral nutrition (via NGT/PEG)       3 (10.0%)       128 (4.919 <t< td=""><td></td><td></td><td></td></t<>			
Chemotherapy > 1st line       3 (10.0%) $367$ (14.19         Vadiotherapy       - $272$ (10.49         arget therapy       - $84$ (3.229         Vormone therapy       - $26$ (1.00%)         Valiative       2 (6.67%) $359$ (13.89         Surgery       2 (6.67%) $504$ (19.39         Cancer related complications       5 (16.7%) $266$ (10.29         herapy related complications       3 (10.0%) $127$ (4.87         Alissing       6 (20.0%) $153$ (5.87)         Infections       5 (16.7%) $381$ (14.69         Seneral       4 (13.3%) $179$ (6.87)         Alissing       2 (6.67%) $239$ (9.17)         Vutrition Treatment       -       2 (6.67%) $239$ (9.17)         Vatrition Treatment       -       - $88$ (3.38)         No special diet       15 (50.0%)       1080 (41.49         nolividualized diet plan       7 (23.3%)       572 (21.99		• •	•
Radiotherapy       -       272 (10.49         arget therapy       -       84 (3.229         formone therapy       -       26 (1.00)         Pallative       2 (6.67%)       359 (13.89         surgery       2 (6.67%)       504 (19.39         Cancer related complications       5 (16.7%)       266 (10.29         herapy related complications       3 (10.0%)       127 (4.879         Alissing       6 (20.0%)       153 (5.879         Infections       -       26 (6.67%)         None       19 (63.3%)       1808 (69.49         ocal       5 (16.7%)       381 (14.69         General       4 (13.3%)       179 (6.87%         Ausing       2 (6.67%)       239 (9.179         Supprised a diet plan       7 (23.3%)       572 (21.99         interal nutrition reatment       -       28 (4.67%)         Variation Treatment       -       2 (6.67%)       426 (16.39         interal nutrition       (via NGT/PEG)       3 (10.0%)       128 (4.919         'areanteral nutrition       -       88 (3.389       240 (9.219         'Dispecial nutrients       -       88 (3.389       240 (9.219         'areanteral nutrition       -       28 (10.09) </td <td></td> <td>• •</td> <td>•</td>		• •	•
arget therapy       -       84 (3.229         formone therapy       -       26 (1.009         valiative       2 (6.67%)       359 (13.89         burgery       2 (6.67%)       504 (19.39         Cancer related complications       5 (16.7%)       266 (10.29         herapy related complications       3 (10.0%)       127 (4.879         Alissing       6 (20.0%)       153 (5.879         nfections       3 (10.0%)       127 (4.879         None       19 (63.3%)       1808 (69.49         ocal       5 (16.7%)       381 (14.69         General       4 (13.3%)       179 (6.879         Alissing       2 (6.67%)       239 (9.179         Nutrition Treatment       7 (23.3%)       572 (21.99         interal nutrition (via NGT/PEG)       3 (10.0%)       128 (4.919         arenteral nutrition       4 (13.3%)       240 (9.219         DNS enriched with special nutrients       88 (3.389       240 (9.219         OS encial nutrients (EPA, branched chained amino       28 (1.079         acids, glutamine, arginine, carnitine)       284 (10.99         Personal preferences       -       284 (10.99         Counselling       1 (3.33%)       355 (13.69         Other <td></td> <td>3 (10.0%)</td> <td>•</td>		3 (10.0%)	•
Addition       -       26 (1.009)         Paillative       2 (6.67%)       359 (13.89)         Surgery       2 (6.67%)       504 (19.39)         Cancer related complications       5 (16.7%)       266 (10.29)         herapy related complications       3 (10.0%)       127 (4.87)         herapy related complications       3 (10.0%)       127 (4.87)         Alissing       6 (20.0%)       153 (5.87)         Infections       -       -         None       19 (63.3%)       1808 (69.49)         ocal       5 (16.7%)       381 (14.69)         General       4 (13.3%)       179 (6.87)         Alissing       2 (6.67%)       239 (9.17)         Supercial diet       15 (50.0%)       1080 (41.49)         Interal nutrition reatment       -       28 (6.67%)         No special diet       15 (50.0%)       1080 (41.49)         Interal nutrition (via NGT/PEG)       3 (10.0%)       128 (4.91)         Varienteral nutrition       4 (13.3%)       240 (9.21)         DNS enriched with special nutrients       -       88 (3.38)         Special nutrients (EPA, branched chained amino       -       28 (10.79)         Acids, glutamine, arginine, carnitine)       -       284 (10.9		-	•
Paillative       2 (6.67%)       359 (13.89         Surgery       2 (6.67%)       504 (19.39)         Cancer related complications       5 (16.7%)       266 (10.29         herapy related complications       3 (10.0%)       127 (4.87)         Alissing       6 (20.0%)       153 (5.87)         nfections       9 (63.3%)       1808 (69.49         occal       5 (16.7%)       381 (14.69         General       4 (13.3%)       179 (6.87)         Alissing       2 (6.67%)       239 (9.17)         Nutrition Treatment       4 (13.3%)       179 (6.87)         vo special diet       15 (50.0%)       1080 (41.49)         noividualized diet plan       7 (23.3%)       572 (21.99)         interal nutrition (via NGT/PEG)       3 (10.0%)       128 (4.91)         Parenteral nutrition (via NGT/PEG)       3 (10.0%)       128 (4.91)         ONS enriched with special nutrients       88 (3.38)       240 (9.219)         DNS enriched with special nutrients       -       28 (10.79)         Counselling       1 (3.33%)       355 (13.60)         Other       -       -       284 (10.99)         Counselling       1 (3.33%)       355 (13.60)		-	•
burgery       2 (6.67%)       504 (19.39)         Cancer related complications       5 (16.7%)       266 (10.29)         herapy related complications       3 (10.0%)       127 (4.87)         Alissing       6 (20.0%)       153 (5.87)         nfections       6 (20.0%)       153 (5.87)         nfections       5 (16.7%)       381 (14.69)         occal       5 (16.7%)       381 (14.69)         General       4 (13.3%)       179 (6.87)         Alissing       2 (6.67%)       239 (9.17)         Mutrition Treatment       9 (6.67%)       239 (9.17)         Nutrition Treatment       7 (23.3%)       572 (21.99)         nergy rich/protein rich ONS       2 (6.67%)       426 (16.39)         interal nutrition (via NGT/PEG)       3 (10.0%)       128 (4.919)         Parenteral nutrition       4 (13.3%)       240 (9.219)         DNS enriched with special nutrients       88 (3.389)       240 (9.219)         ONS enriched with special nutrients       88 (3.389)       28 (10.79)         acids, glutamine, arginine, carnitine)       -       284 (10.99)         Counselling       1 (3.33%)       355 (13.69)         Other       -       284 (10.99)		-	•
Cancer related complications       5 (16.7%)       266 (10.29)         herapy related complications       3 (10.0%)       127 (4.879)         Alissing       6 (20.0%)       153 (5.879)         nfections       9 (63.3%)       1808 (69.49)         vone       19 (63.3%)       1808 (69.49)         ocal       5 (16.7%)       381 (14.69)         General       4 (13.3%)       179 (6.879)         Alissing       2 (6.67%)       239 (9.179)         Autrition Treatment       7 (23.3%)       572 (21.99)         No special diet       15 (50.0%)       1080 (41.49)         ndividualized diet plan       7 (23.3%)       572 (21.99)         inergy rich/protein rich ONS       2 (6.67%)       426 (16.39)         interal nutrition (via NGT/PEG)       3 (10.0%)       128 (4.919)         Parenteral nutrition       4 (13.3%)       240 (9.219)         ONS enriched with special nutrients       -       88 (3.389)         ipecial nutrients (EPA, branched chained amino       -       28 (1.079)         acids, glutamine, arginine, carnitine)       -       284 (10.99)         Counselling       1 (3.33%)       355 (13.69)         Other       -       202 (7.759)	Palliative	· · ·	•
herapy related complications       3 (10.0%)       127 (4.879         Alissing       6 (20.0%)       153 (5.879         nfections       9 (63.3%)       1808 (69.49         None       19 (63.3%)       1808 (69.49         ocal       5 (16.7%)       381 (14.69         General       4 (13.3%)       179 (6.879         Autrition Treatment       2 (6.67%)       239 (9.179         Autrition Treatment       7 (23.3%)       572 (21.99         Inergy rich/protein rich ONS       2 (6.67%)       426 (16.39         Correral nutrition (via NGT/PEG)       3 (10.0%)       128 (4.919         Parenteral nutrition       4 (13.3%)       240 (9.219         ONS enriched with special nutrients       -       88 (3.389         Special nutrients (EPA, branched chained amino       -       28 (1.079         acids, glutamine, arginine, carnitine)       -       284 (10.99         Counselling       1 (3.33%)       355 (13.69         Other       -       202 (7.759	Surgery	· · ·	504 (19.3%
Alissing       6 (20.0%)       153 (5.879)         Infections       19 (63.3%)       1808 (69.4%)         ocal       5 (16.7%)       381 (14.6%)         General       4 (13.3%)       179 (6.87%)         Autrition Treatment       2 (6.67%)       239 (9.17%)         Nutrition Treatment       7 (23.3%)       572 (21.9%)         No special diet       15 (50.0%)       1080 (41.4%)         Interal nutrition (via NGT/PEG)       2 (6.67%)       426 (16.3%)         Parenteral nutrition (via NGT/PEG)       3 (10.0%)       128 (4.91%)         Parenteral nutrition       4 (13.3%)       240 (9.21%)         DNS enriched with special nutrients       -       88 (3.38%)         special nutrients (EPA, branched chained amino       -       28 (1.07%)         acids, glutamine, arginine, carnitine)       -       284 (10.9%)         Counselling       1 (3.33%)       355 (13.6%)         Other       -       202 (7.75%)	Cancer related complications	5 (16.7%)	266 (10.2%
Infections       19 (63.3%)       1808 (69.4%         ocal       5 (16.7%)       381 (14.6%         General       4 (13.3%)       179 (6.87%         Missing       2 (6.67%)       239 (9.17%         Nutrition Treatment       2 (6.67%)       239 (9.17%         No special diet       15 (50.0%)       1080 (41.4%         Individualized diet plan       7 (23.3%)       572 (21.9%         Interal nutrition (via NGT/PEG)       2 (6.67%)       426 (16.3%)         Parenteral nutrition       (via NGT/PEG)       3 (10.0%)       128 (4.91%)         ONS enriched with special nutrients       -       88 (3.38%)         Special nutrients (EPA, branched chained amino       -       28 (1.07%)         acids, glutamine, arginine, carnitine)       -       284 (10.9%)         Counselling       1 (3.33%)       355 (13.6%)         Other       -       202 (7.75%)	Therapy related complications	3 (10.0%)	127 (4.87%
None         19 (63.3%)         1808 (69.49           ocal         5 (16.7%)         381 (14.69           General         4 (13.3%)         179 (6.879           Ausing         2 (6.67%)         239 (9.179           Autrition Treatment         2 (6.67%)         239 (9.179           Autrition Treatment         7 (23.3%)         572 (21.99           Individualized diet plan         7 (23.3%)         572 (21.99           Energy rich/protein rich ONS         2 (6.67%)         426 (16.39           Enteral nutrition (via NGT/PEG)         3 (10.0%)         128 (4.919           Parenteral nutrition         4 (13.3%)         240 (9.219           DNS enriched with special nutrients         88 (3.389         240 (9.219           DNS enriched with special nutrients         -         28 (1.079           Counselling         -         284 (10.99           Outselling         1 (3.33%)         355 (13.69           Other         -         202 (7.759	Missing	6 (20.0%)	153 (5.87%
None         19 (63.3%)         1808 (69.49           ocal         5 (16.7%)         381 (14.69           General         4 (13.3%)         179 (6.879           Ausing         2 (6.67%)         239 (9.179           Autrition Treatment         2 (6.67%)         239 (9.179           Autrition Treatment         7 (23.3%)         572 (21.99           Individualized diet plan         7 (23.3%)         572 (21.99           Energy rich/protein rich ONS         2 (6.67%)         426 (16.39           Enteral nutrition (via NGT/PEG)         3 (10.0%)         128 (4.919           Parenteral nutrition         4 (13.3%)         240 (9.219           DNS enriched with special nutrients         88 (3.389         240 (9.219           DNS enriched with special nutrients         -         28 (1.079           Counselling         -         284 (10.99           Outselling         1 (3.33%)         355 (13.69           Other         -         202 (7.759	Infections		
cocal         5 (16.7%)         381 (14.69)           General         4 (13.3%)         179 (6.879)           Missing         2 (6.67%)         239 (9.179)           Jutrition Treatment         2 (6.67%)         239 (9.179)           No special diet         15 (50.0%)         1080 (41.49)           ndividualized diet plan         7 (23.3%)         572 (21.99)           Energy rich/protein rich ONS         2 (6.67%)         426 (16.39)           Enteral nutrition (via NGT/PEG)         3 (10.0%)         128 (4.919)           Parenteral nutrition         4 (13.3%)         240 (9.219)           DNS enriched with special nutrients         -         88 (3.389)           Special nutrients (EPA, branched chained amino         -         28 (1.079)           Counselling         -         284 (10.99)         -           Dther         -         202 (7.759)		19 (63 3%)	1808 (69 4%
General       4 (13.3%)       179 (6.87%)         Missing       2 (6.67%)       239 (9.17%)         Autrition Treatment       15 (50.0%)       1080 (41.4%)         No special diet       15 (50.0%)       1080 (41.4%)         ndividualized diet plan       7 (23.3%)       572 (21.9%)         Energy rich/protein rich ONS       2 (6.67%)       426 (16.3%)         Enteral nutrition (via NGT/PEG)       3 (10.0%)       128 (4.91%)         Parenteral nutrition       4 (13.3%)       240 (9.21%)         DNS enriched with special nutrients       -       88 (3.38%)         Special nutrients (EPA, branched chained amino       -       28 (1.07%)         Acids, glutamine, arginine, carnitine)       -       284 (10.9%)         Counselling       1 (3.33%)       355 (13.6%)         Other       -       202 (7.75%)		• •	•
Missing       2 (6.67%)       239 (9.179)         Autrition Treatment       15 (50.0%)       1080 (41.49)         No special diet       15 (50.0%)       1080 (41.49)         Individualized diet plan       7 (23.3%)       572 (21.99)         Energy rich/protein rich ONS       2 (6.67%)       426 (16.39)         Enteral nutrition (via NGT/PEG)       3 (10.0%)       128 (4.919)         Parenteral nutrition       4 (13.3%)       240 (9.219)         DNS enriched with special nutrients       -       88 (3.389)         Special nutrients (EPA, branched chained amino       -       28 (1.079)         acids, glutamine, arginine, carnitine)       -       284 (10.99)         Personal preferences       -       202 (7.759)         Other       -       202 (7.759)		• • •	•
No special diet         15 (50.0%)         1080 (41.4%)           Individualized diet plan         7 (23.3%)         572 (21.9%)           Energy rich/protein rich ONS         2 (6.67%)         426 (16.3%)           Enteral nutrition (via NGT/PEG)         3 (10.0%)         128 (4.91%)           Parenteral nutrition         4 (13.3%)         240 (9.21%)           Parenteral nutrition         4 (13.3%)         240 (9.21%)           Parenteral nutrients (EPA, branched chained amino         -         88 (3.38%)           Special nutrients (EPA, branched chained amino         -         284 (10.9%)           Personal preferences         -         284 (10.9%)           Counselling         1 (3.33%)         355 (13.6%)           Other         -         202 (7.75%)	Missing	• •	239 (9.17%
No special diet         15 (50.0%)         1080 (41.4%)           Individualized diet plan         7 (23.3%)         572 (21.9%)           Energy rich/protein rich ONS         2 (6.67%)         426 (16.3%)           Enteral nutrition (via NGT/PEG)         3 (10.0%)         128 (4.91%)           Parenteral nutrition         4 (13.3%)         240 (9.21%)           Parenteral nutrition         4 (13.3%)         240 (9.21%)           Parenteral nutrients (EPA, branched chained amino         -         88 (3.38%)           Special nutrients (EPA, branched chained amino         -         284 (10.9%)           Personal preferences         -         284 (10.9%)           Counselling         1 (3.33%)         355 (13.6%)           Other         -         202 (7.75%)	<b>.</b>		
Individualized diet plan       7 (23.3%)       572 (21.9%)         Energy rich/protein rich ONS       2 (6.67%)       426 (16.3%)         Enteral nutrition (via NGT/PEG)       3 (10.0%)       128 (4.91%)         Parenteral nutrition       4 (13.3%)       240 (9.21%)         Parenteral nutrition       4 (13.3%)       240 (9.21%)         ONS enriched with special nutrients       -       88 (3.38%)         Special nutrients (EPA, branched chained amino       -       28 (1.07%)         Acids, glutamine, arginine, carnitine)       -       284 (10.9%)         Personal preferences       -       284 (10.9%)         Counselling       1 (3.33%)       355 (13.6%)         Other       -       202 (7.75%)			1000 (41 40)
Inergy rich/protein rich ONS2 (6.67%)426 (16.3%)Interal nutrition (via NGT/PEG)3 (10.0%)128 (4.91%)Parenteral nutrition4 (13.3%)240 (9.21%)Parenteral nutrients-88 (3.38%)ONS enriched with special nutrients-88 (3.38%)ONS enriched with special nutrients-28 (1.07%)ONS enriched signine, arginine, carnitine)-284 (10.9%)Personal preferences-284 (10.9%)Counselling1 (3.33%)355 (13.6%)Other-202 (7.75%)		• •	•
Enteral nutrition (via NGT/PEG)3 (10.0%)128 (4.91%)Parenteral nutrition4 (13.3%)240 (9.21%)Parenteral nutrition4 (13.3%)240 (9.21%)ONS enriched with special nutrients-88 (3.38%)Special nutrients (EPA, branched chained amino-28 (1.07%)Courselling-284 (10.9%)Counselling1 (3.33%)355 (13.6%)Other-202 (7.75%)			•
Parenteral nutrition 4 (13.3%) 240 (9.21% ONS enriched with special nutrients - 88 (3.38% Special nutrients (EPA, branched chained amino - 28 (1.07% acids, glutamine, arginine, carnitine) Personal preferences - 284 (10.9% Counselling 1 (3.33%) 355 (13.6% Other - 202 (7.75%)		• •	•
DNS enriched with special nutrients-88 (3.38%Special nutrients (EPA, branched chained amino-28 (1.07%acids, glutamine, arginine, carnitine)-284 (10.9%Personal preferences-284 (10.9%Counselling1 (3.33%)355 (13.6%Other-202 (7.75%		. ,	•
Special nutrients (EPA, branched chained amino-28 (1.07%acids, glutamine, arginine, carnitine)-284 (10.9%Personal preferences-284 (10.9%Counselling1 (3.33%)355 (13.6%Other-202 (7.75%		4 (13.3%)	•
acids, glutamine, arginine, carnitine) Personal preferences - 284 (10.9% Counselling 1 (3.33%) 355 (13.6% Other - 202 (7.75%		-	•
Personal preferences         -         284 (10.9%           Counselling         1 (3.33%)         355 (13.6%           Other         -         202 (7.75%		-	28 (1.07%
Counselling         1 (3.33%)         355 (13.69           Other         -         202 (7.759	acids, glutamine, arginine, carnitine)		
Dther - 202 (7.75%	Personal preferences	-	284 (10.9%
	Counselling	1 (3.33%)	355 (13.6%
utritionDay Nov. 2015 10/05/2016 12:14 - Page 7 of 11	Other	-	202 (7.75%
	nutritionDay Nov. 2015 10/05/2016 12:14 - Page 7 of 11		



## Missing

-

-

PATIENTS REPORT ("Sheet 3"):		YOUR RESULTS	REFERENCE RESULTS
Number of patients completing		30	2474
Body weight prior to becoming	ill	70 [52-149]	73 [30-199]
Actual body weight		67 [48-148]	67 [10-200]
Change in weight was			
Intentional		1 (3.33%)	64 (2.45%)
Unintentional		15 (50.0%)	· · ·
Weight is stable Missing		4 (13.3%) 1 (3.33%)	318 (12.2%) 111 (4.26%)
During the last week			
Patients who have had pain:			
Not at all		11 (36.7%)	709 (27.2%)
A little		3 (10.0%)	596 (22.9%)
Quite a bit		7 (23.3%)	419 (16.1%)
Very much		1 (3.33%)	332 (12.7%)
Missing		8 (26.7%)	530 (20.3%)
Patients who needed a rest:			
Not at all		6 (20.0%)	391 (15.0%)
Alittle		5 (16.7%)	592 (22.7%)
Quite a bit		10 (33.3%)	575 (22.1%)
Very much Missing		- 8 (26.7%)	488 (18.7%) 540 (20.7%)
Wilson IQ		0 (20.770)	540 (20.776)
Patients who felt weak:		2(10,00)	400 (14 10/)
Not at all A little		3 (10.0%) 6 (20.0%)	420 (16.1%) 583 (22.4%)
Quite a bit		11 (36.7%)	535 (22.4%)
Very much		2 (6.67%)	499 (19.1%)
Missing		8 (26.7%)	544 (20.9%)
Detients who felt depressed			
Patients who felt depressed: Not at all		9 (30.0%)	775 (29.7%)
Alittle		6 (20.0%)	601 (23.1%)
Quite a bit		4 (13.3%)	356 (13.7%)
Very much		3 (10.0%)	298 (11.4%)
Missing		8 (26.7%)	546 (20.9%)
Patients who were tired:			
Not at all		5 (16.7%)	445 (17.1%)
Alittle		6 (20.0%)	611 (23.4%)
Quite a bit		9 (30.0%)	534 (20.5%)
Very much		2 (6.67%)	449 (17.2%)
Missing		8 (26.7%)	539 (20.7%)
Patients whose pain interfered	with their daily		
activities:			
Not at all		8 (26.7%)	766 (29.4%)
A little Quite a bit		3 (10.0%) 10 (33.3%)	458 (17.6%) 366 (14.0%)
nutritionDay Nov. 2015	10/05/2016 12:14 - Page 9 of 11	10 (33.370)	
HamonDay Nov. 2015	10/00/2010 12.14 Fayer 9 01 11		

nutritionDay

Very much	1 (3.33%)	398 (15.3%
Missing	8 (26.7%)	582 (22.3%
Detients who looked on estite.		
Patients who lacked appetite: Not at all	10 (22 29/)	770 (20 00/
	10 (33.3%)	779 (29.9%
A little	5 (16.7%)	485 (18.6%
Quite a bit	6 (20.0%)	378 (14.5%
Very much	1 (3.33%)	391 (15.0%
Missing	8 (26.7%)	548 (21.0%
Just now		
Patients who have pain:		
Not at all	12 (40.0%)	901 (34.6%
A little	5 (16.7%)	676 (25.9%
Quite a bit	3 (10.0%)	327 (12.5%
Very much	2 (6.67%)	152 (5.83%
Missing	8 (26.7%)	533 (20.4%
Patients who need a rest:		
Not at all	9 (30.0%)	438 (16.8%
A little	6 (20.0%)	705 (27.0%
Quite a bit	4 (13.3%)	555 (21.3%
Very much	2 (6.67%)	347 (13.3%
Missing	9 (30.0%)	538 (20.6%
Patients who feel weak:		
Not at all	5 (16.7%)	503 (19.3%
A little	7 (23.3%)	647 (24.8%
Quite a bit	9 (30.0%)	538 (20.6%
Very much	1 (3.33%)	352 (13.5%
Missing	8 (26.7%)	541 (20.8%
Patients who are depressed:		
Not at all	11 (36.7%)	915 (35.1%
A little	6 (20.0%)	559 (21.4%
Quite a bit	4 (13.3%)	332 (12.79
Very much	· · · · · · · · · · · · · · · · · · ·	225 (8.63%
Missing	9 (30.0%)	549 (21.1%
Patients who are tired:		
Not at all	8 (26.7%)	537 (20.6%
A little	6 (20.0%)	669 (25.7%
Quite a bit	6 (20.0%)	500 (19.2%
Very much	1 (3.33%)	326 (12.5%
Missing	9 (30.0%)	549 (21.1%
Patients whose pain interferes with their daily		
activities:		
Not at all	11 (36.7%)	881 (33.8%
A little	3 (10.0%)	483 (18.5%
Quite a bit	6 (20.0%)	346 (13.3%
Very much	1 (3.33%)	301 (11.5%
Missing	9 (30.0%)	563 (21.6%
TAIL STILLY	7 (30.070)	505 (21.07



Patients who lack appetite:		
Not at all	9 (30.0%)	882 (33.8%)
Alittle	7 (23.3%)	503 (19.3%)
Quite a bit	4 (13.3%)	341 (13.1%)
	4 (13.370)	· · ·
Very much	-	309 (11.9%)
Missing	10 (33.3%)	547 (21.0%)
Descens for change in appetite /feed intoke		
Reasons for change in appetite/food intake	( (20,0%))	
Nausea/Vomiting	6 (20.0%)	396 (15.2%)
Inflammation in mouth	1 (3.33%)	111 (4.26%)
Pain	2 (6.67%)	288 (11.0%)
Constipation	1 (3.33%)	167 (6.41%)
Diarrhea	-	107 (4.10%)
	4 (13.3%)	318 (12.2%)
Change in taste/smell		
Early satiation/Loss of appetite	3 (10.0%)	520 (19.9%)
Other	9 (30.0%)	340 (13.0%)
Missing	1 (3.33%)	86 (3.30%)
Maximum activity performed by patients		
Able to do sports	1 (3.33%)	56 (2.15%)
Fully active	7 (23.3%)	316 (12.1%)
Able to carry out light activities	4 (13.3%)	501 (19.2%)
Able to carry out self-care	4 (13.3%)	497 (19.1%)
Able to carry out limited self-care	2 (6.67%)	361 (13.8%)
5		
Confined to bed or chair	4 (13.3%)	312 (12.0%)
Missing	8 (26.7%)	550 (21.1%)
Patient takes additional (without prescription)		
· · · ·		1 404 (5 4 70/)
Nothing	16 (53.3%)	1426 (54.7%)
Herbal tea	1 (3.33%)	198 (7.59%)
Nutritional supplements	-	199 (7.63%)
Multivitamin	1 (3.33%)	80 (3.07%)
Other medication	2 (6.67%)	85 (3.26%)
	( )	· · ·
Other	1 (3.33%)	· · ·
Missing	9 (30.0%)	612 (23.5%)
Additional activities performed		
Nothing	18 (60.0%)	1175 (56 601)
8	18 (00.0%)	1475 (56.6%)
Psychotherapy	-	70 (2.69%)
Yoga	-	24 (0.92%)
Meditation	-	82 (3.15%)
Progressive muscle relaxation	-	49 (1.88%)
Qigong	-	3 (0.12%)
Other	/ (1 2 20/)	
	4 (13.3%)	225 (8.63%)
Missing	8 (26.7%)	713 (27.3%)
Patients having difficulties in complying with	3 (10.0%)	545 (20.9%)
treatment	5 (10.070)	J+J (ZU.770)
Patients needing help to complete questionnaire	13 (43.3%)	1332 <b>(</b> 51.1% <b>)</b>
Patients believing that including nutrition in their therapeutic approach could provide relevant benefit	14 (46.7%)	1364 (52.3%)
to them		
IN INEM		

